# Carcinoid Heart Disease: A Rare Complication of Metastatic Neuroendocrine Tumor

**Authors:** John P Martinez Ponce, Oskar Ubysz, Thomas Vanhecke

PMC · DOI: 10.7759/cureus.78148 · 2025-01-28

## TL;DR

This paper presents a case of a rare heart condition caused by a neuroendocrine tumor, successfully treated with valve replacement surgery.

## Contribution

The paper highlights a successful surgical treatment approach for carcinoid heart disease, a rare complication of metastatic neuroendocrine tumors.

## Key findings

- Transthoracic echocardiogram showed severe tricuspid regurgitation and pulmonary valve stenosis.
- Medical therapies failed to reverse valvular pathology, but valve replacement resolved symptoms.
- Elevated 5-HIAA levels and imaging confirmed the presence of metastatic neuroendocrine tumors.

## Abstract

Carcinoid heart disease (CHD), also known as Hedinger syndrome, is a rare but significant cardiac complication associated with metastatic neuroendocrine tumors (NETs). These tumors secret bioactive substances such as serotonin, leading to fibrotic changes primarily affecting the right-sided heart valves. A case study involving a 69-year-old male presented with a four-month history of diarrhea and a new systolic heart murmur. Transthoracic echocardiogram (TTE) results indicated a left ventricular ejection fraction (LVEF) of 60% to 65%, with severe tricuspid regurgitation and pulmonary valve stenosis. Elevated levels of 5-hydroxyindoleacetic acid (5-HIAA) were detected in a 24-hour urine test, and imaging revealed multiple hypoechoic masses in the liver and mesenteric masses adherent to the small intestine. Furthermore, a biopsy confirmed the diagnosis of a NET. Medical therapy like long-acting somatostatin injection and a peptide receptor radionuclide therapy was ineffective in reversing established valvular pathology, and the patient continued to experience clinical decline, suffering from right-sided heart failure. The patient was able to undergo combined tricuspid and pulmonary valve replacement, which resolved his symptoms. This case exemplifies the successful treatment of a rare syndrome leading to right heart failure.

## Linked entities

- **Chemicals:** 5-hydroxyindoleacetic acid (PubChem CID 1826), serotonin (PubChem CID 5202)
- **Diseases:** Carcinoid heart disease (MONDO:0043529), neuroendocrine tumor (MONDO:0019496)

## Full-text entities

- **Genes:** SST (somatostatin) [NCBI Gene 6750] {aka SMST, SST1}
- **Diseases:** valvular (MESH:D006349), NETs (MESH:D018358), heart failure (MESH:D006333), tumors (MESH:D009369), Hedinger syndrome (MESH:D013577), systolic heart murmur (MESH:D006337), Metastatic (MESH:D000092182), tricuspid regurgitation (MESH:D014262), diarrhea (MESH:D003967), CHD (MESH:D002275), cardiac complication (MESH:D006331), pulmonary valve stenosis (MESH:D011666)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11872146/full.md

---
Source: https://tomesphere.com/paper/PMC11872146